This trial is testing whether a new vaccine is non-inferior to the current standard vaccine for infants and toddlers. It is also looking at the antibody response to the new vaccine and comparing it to the current standard.
1 Primary · 11 Secondary · Reporting Duration: 30 days after the second dose of meningococcal vaccine
1070 Total Participants · 4 Treatment Groups
Primary Treatment: Hepatitis B Vaccine · No Placebo Group · Phase 3
Age < 18 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Investigational Site Number 8400076||100.0%|